NewsRoom Articles - Page 47 of 48

FridayJun 17, 2022 9:45 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Focused on Growing Out Their B2B and B2C Verticals

Golden Matrix Group, Inc has been a major beneficiary of the growth in online gaming as well as the ongoing regulation and legalization of online casinos and online sports betting GloballyThe Company has expanded its white-label B2B offering through the launch of the GM-X and GM-Ag turnkey solution, a complete software package designed to allow land-based operators to transition into providing online operationsGMGI have separately sought to bolster their B2C offering, most recently through the acquisition of a controlling stake in UK-based RKingsCompetitions, a leading online competition company in the UK and Northern IrelandIn addition to contributing over $5.1 million…

FridayJun 17, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategyJustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only programFlora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the acquisition of 100%…

WednesdayJun 15, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertensionThe company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filingThe pre-IND meeting will confirm the details of the company’s IND-enabling programLexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process…

WednesdayJun 15, 2022 9:00 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Leverages AI-Powered Platform to Maximize Online Gaming Profits

iGaming customer acquisition costs rising, reducing operator profitabilityGMGI offers AI-powered iGaming software that provides partners with customer data that boosts monetization strategies, increases player retentionSystem generates skill and game-preference data that enables operators to offer incentives that prolong activity and increase returns Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, leverages the power of AI to maximize profits for its growing B2B customer base. The company offers highly modular, configurable, turnkey, and white label gaming platforms that are compatible with all major browsers, operating systems, and devices. With a focus on…

TuesdayJun 14, 2022 9:00 am

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisionsAditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus. Though the COVID-19 pandemic is now…

MondayJun 13, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector Its management is confident that its research and technology development investment will pay off and provide greater consumer satisfaction. In 2019, it was estimated that at least 1.1 billion people globally smoked cigarettes regularly. 780 million, representing 71% of the global smoking population, noted that they wanted to…

FridayJun 10, 2022 9:00 am

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejectionAditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerabilityWhile immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemicHealth officials also…

FridayJun 03, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodiesLexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapiesThe company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressureA driving focus of the company’s R&D has been to improve the speed of onset,…

TuesdayMay 31, 2022 10:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Working to Alleviate Consumer Anxiety by Offering EVs with 600-Plus Mile Range

J.D. Power survey reports range was factor most cited in deciding what EV to buyMullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV spaceRecognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 Energy.gov study…

TuesdayMay 31, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issueCYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substanceKernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000